



Investor Presentation

*RBC Road Show London,
January 2020*



*...at Hansa Biopharma we envision a world where all patients
with rare immunologic diseases can lead long and healthy lives...*

Forward-looking statement

This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Hansa Biopharma's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of Hansa Biopharma's strategy and its ability to further grow, risks associated with the development and/or approval of Hansa Biopharma's products candidates, ongoing clinical trials and expected trial results, the ability to commercialize imlifidase, technology changes and new products in Hansa Biopharma's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

No assurance can be given that such expectations will prove to have been correct. Hansa Biopharma disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Table of contents

1.	Q4 2019 Business Update.....	4
2.	Company overview.....	12
3.	Imlifidase in kidney transplantations.....	22
4.	Completed and ongoing studies in kidney..... transplantation.....	28
5.	CMC Imlifidase.....	37
6.	Clinical development programs.....	43
7.	Preclinical programs.....	51

Q4'19 Business Update



Agreement with the FDA on a regulatory path forward in the US; EMA review process on track

Imlifidase in kidney transplantation

U.S. (FDA)

- Agreement with FDA to focus on patients with a very high unmet medical need
- Hansa Biopharma will conduct a randomized, controlled clinical study in a limited and well-defined group of highly sensitized kidney patients ($\geq 99.9\%$ cPRA) using eGFR after 12 months as a surrogate endpoint
- Results from this clinical study could support BLA submission by 2023 under the accelerated approval pathway

Europe (EMA)

- Regulatory review process progressing as expected; Day 120 answers submitted on December 22, 2019
- Opinion from Committee for Medicinal Products for Human Use (CHMP) expected during the second quarter of 2020
- Decision by European Commission expected during the summer 2020





A clinical study targeting ~50 highly sensitized patients could support BLA submission in the US by 2023

Clinical benefit measured through eGFR

- The new study will be a randomized controlled clinical study targeting approximately 50 patients, awaiting a deceased donor transplantation with a cPRA of 99.9% and above
- When a donor kidney becomes available patient will be randomized to either an imlifidase enabled transplantation or to a control group who will remain on the waitlist
- The clinical benefit of imlifidase will be measured after 12 months by a surrogate endpoint, eGFR kidney function, and analyzed in context of the U.S. Kidney Allocation System
- In 2019 around 3,000 patients with a cPRA level of 99.9% or above were registered on the waitlist. This group has very limited access to transplantation


Focused launch strategy optimizes patient access to imlifidase

Strong outreach with limited footprint in EU

- Building awareness through MSL and Patient Advocacy
 - MSL organization established in key markets
 - MSLs educate KOLs and physicians at transplantation clinics
- Potential launch based on an assumed conditional approval in the first countries in the second half of 2020 following pricing and reimbursement
- A sequenced and focused launch strategy
 - In Europe, 70-80% of all kidney transplantations are performed at 5-7 top centers in each countries
 - Introduction of imlifidase through leading transplantation clinics and experts to ensure positive clinical outcomes
 - Post-approval efficacy study (PAES) to be initiated



The EMA process towards marketing authorization



Enrollment in Anti-GBM close to completion. First two patients treated in GBS and AMR respectively

Ongoing studies evaluating safety and efficacy

Enrollment



Anti-GBM

- 14/15 patients enrolled in anti-GBM
- Enrollment expected to be completed Q1 2020



Antibody Mediated Rejection (AMR)

- 2/30 patients treated with imlifidase in AMR. 6/8 sites have been initiated to recruit patients in the US, Europe and Australia
- Enrollment expected to be completed H2 2020



Guillain-Barré Syndrome (GBS)

- 2/30 patients enrolled. 6/10 sites are recruiting patients across France and the UK
- Enrollment expected to be completed in H1 2021

■ Patients enrolled
■ Patients left



Broad pipeline in transplantation and auto-immune diseases

Candidate / Projecting	Indication	Research/ Preclinical	Phase 1 ¹	Potentially Pivotal program/ Phase 2 ²	Marketing Authorization	Marketed	Next Anticipated Milestone
Imlifidase	Kidney transplantation in highly sensitized patients				*)		EU: CHMP Opinion US: Initiation of clinical study to support BLA submission in 2023
	Anti-GBM antibody disease						Complete enrolment
	Antibody mediated kidney transplant rejection (AMR)						Complete enrolment
	Guillain-Barré syndrome						Complete enrolment
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology						Development of CMC process / Tox studies
EnzE	Cancer immunotherapy						Research phase



Completed



Ongoing


¹ Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7).

² Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)

*) EMA: In imlifidase for kidney transplantation we have filed for conditional approval after completion of phase 2.
A post-approval study would need to be executed in case of approval.

FDA: Agreement with the FDA on a regulatory path forward in the US. New clinical study to support BLA submission by 2023

Upcoming milestones



Company Overview



Hansa Biopharma at a glance



Company background

- Founded 2007 with HQ in Lund, Sweden
- Sören Tulstrup, CEO – Ulf Wiinberg, Chairman
- ~74 employees (~3/4 in R&D) at Dec 30, 2019
- Operations in Sweden, US & Europe
- Market cap: SEK ~3.5bn (USD ~350m) Dec 30, 2019
- Listed on Nasdaq OMX Stockholm (HNSA)



Leader in immunomodulatory enzymes for rare IgG-mediated diseases

- Imlifidase is a unique IgG antibody-cleaving enzyme
- Imlifidase has been studied in five clinical studies in kidney transplantation
- Imlifidase has been published in peer-reviewed journals (e.g. New England Journal of Medicine and the American Journal of Transplantation)
- If approved, Imlifidase may have the potential to meet a large unmet need and transforming the lives of people with rare disease



Broad pipeline in transplantation and autoimmune diseases

- Lead indication in kidney transplantation in highly sensitized patients (MAA under review by EMA)
- Anti-GBM antibody disease (Phase 2)
- Antibody mediated kidney transplant rejection (AMR) (Phase 2)
- Guillain-Barré syndrome (Phase 2)
- NiceR - Recurring treatment in autoimmune disease, transplantation and oncology (Preclinical)
- EnzE – Cancer immunotherapy (Preclinical)



Key Financials

• Cash position	Q4'19* SEK 601m	FY'19* SEK 601m
• R&D expenses	Q4'19* SEK -58m	FY'19* SEK -193m
• SG&A expenses	Q4'19* SEK -53m	FY'19* SEK -167m
• Operating Profits/Loss	Q4'19* SEK -110	FY'19* SEK -360m

*...at Hansa Biopharma we envision
a world where all patients with rare
immunologic diseases can lead
long and healthy lives...*




Imlifidase – a novel approach to eliminate pathogenic IgG




Origins from *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection




Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')₂ fragment and one homo-dimeric Fc-fragment



Imlifidase inactivates IgG in 2 hours

- Rapid onset of action that inactivates IgG below detectable level in 2 hours
- IgG antibody-free window for approximately one week



Our Equity Story



Targeting rare diseases with a high unmet medical need

- Imlifidase is a unique IgG antibody-cleaving enzyme with a rapid onset of action and high specificity for inactivation of IgG in patients with rare immunologic diseases



Preparing for commercialization

- Preparing for potential launch of imlifidase under conditional approval in core European markets starting in H2 2020. MAA is currently under review by EMA
- Imlifidase to be launched through Hansa's own medical and commercial organization, while the company is expected to pursue a partnership strategy outside core markets
- In the US a clear regulatory path has been agreed with the FDA that support potential submission of a BLA in 2023 under the accelerated approval pathway
- Broad technology protection with patent coverage throughout 2035 in key markets and orphan drug designation in both the US/EU in our lead indications




Evolution into a fully integrated biopharmaceutical company

- Controlling the full value chain from early discovery through commercialization to maximize the value creation and capture




Leveraging our proprietary antibody cleaving enzyme technology

- Advancing our pipeline with three phase 2 programs in transplantation and acute autoimmune diseases.
- New set of modified enzymes under development (NiceR program) for repeat dosing; potentially enabling treatment in relapsing diseases and oncology
- Exploring potential combination therapies in oncology with IgG-modulating enzymes and gene therapy in patients with neutralizing antibodies through potential partnerships



Potential indication universe



Our unique enzyme technology platform offers significant potential for growth and expansion

Our strategic priorities



Establish a commercial and medical infrastructure in Europe



Attain marketing authorization in Europe for imlifidase as a treatment for highly sensitized patients to enable kidney transplantation



Investigate the potential of imlifidase in autoimmune indications and post transplantation




Advance a new set of immunomodulatory enzymes designed for repeat dosing in relapsing diseases (NiceR) into clinical development



Explore potential combination therapies with imlifidase in oncology and in gene therapy in patients with neutralizing antibodies

Our road map for growth and expansion



Experienced Board and Executive Committee with many years in the global healthcare industry

Executive Committee



Sören Tulstrup

President & CEO (2018)
+30 years in the Healthcare sector
Ex-CEO at Vifor Pharma
Ex-SVP at Shire Pharmaceuticals
Ex-CEO at Santaris Pharma



Christian Kjellman

SVP & CSO (2008)
+20 years in the Healthcare sector
Ex-Head of Research at Cartela
Ex-Senior Scientist at Biogen
MSc Chemical Biology, PhD in Tumour Immunology from Lund University



Donato Spota

SVP & CFO (2019)
+20 years in the Healthcare sector
Ex-CFO Basilea Pharmaceutica
Senior Finance roles at Roche



Henk D. van Troostwijk

SVP & CCO (2016)
+20 years in the Healthcare sector
Ex-GM at Raptor Pharmaceuticals
Ex-BU Director at Genzyme Europe



Max Sakajja

VP, Corporate Strategy (2017)
Ex-M&A Director at SOBI
Ex-Global Product and Service Development Manager at Envirota
Ex-independent life science industry management consultant



Anne Säfström Lanner

VP, Global HR (2019)
Ex-Head of HR European Spallation Source
Ex-Head of HR Cellavision



Ulf Wiinberg

Chairman (2016)
+30 years in the Healthcare sector
Ex-CEO at Lundbeck (2008-14)
Ex-President at Wyeth of the global consumer health care and European Pharma business



Birgit Stattin Norinder

Board Member (2012)
Ex-CEO and Chairman at Prolifix Ltd.
Ex-SVP, Pharmacia & Upjohn
Member of Hansa Biopharma Scientific Committee and Remuneration Committee.



Anders Gersel Pedersen

Board Member (2018)
+30 years in the Healthcare sector
Ex-EVP R&D H.Lundbeck
Chairman of Hansa Biopharma's Scientific Committee.



Eva Nilsagård

Board Member (2019)
interim CFO at OptiGroup AB
CEO of Nilsagård Consulting AB
Ex-CFO of Vitrolife and Plasta
Chairman of Hansa Biopharma's Audit Committee.



Mats Blom


Board Member (2019)
CFO of NorthSea Therapeutics
Ex-CFO Zealand Pharma
Member of Hansa Biopharma's Audit Committee



Andreas Eggert

Board Member (2018)
Ex-SVP at H. Lundbeck A/S
Ex-VP Wyeth/Pfizer in the U.S.
Member of Hansa Biopharma's Audit Committee and Remuneration Committee.



From technology development to potential commercialisation in 13 years



Strong technology protection through patents and orphan drug designation

Patent coverage out to 2035 in key markets

- Hansa Biopharma's portfolio consist of 11 separate patent families incl. 7 patent families in relations to the use of imlifidase (granted/pending)
- Patents cover use of isolated imlifidase in:



Orphan drug designation

- Orphan drug designation is granted to drugs intended for rare diseases (affecting max 5 patients in 10,000 persons in EU or affecting less than 200,000 patients in the US).
- Designation provides development and commercial incentives incl. 10 years market exclusivity in EU and 7 years in the US

EMA
Orphan drug designation


- Imlifidase for the prevention of graft rejection following solid organ transplantation (2017)
- Imlifidase for the treatment of the rare and acute disease anti-GBM (2018)

FDA
Orphan drug designation


- Imlifidase for the prevention of antibody-mediated organ rejection in solid organ transplantation (2015)
- Imlifidase for the treatment of Guillian-Barré Syndrome (2018)
- Imlifidase for the treatment of the rare and acute disease anti-GBM (2018)

Hansa Biopharma is financed into 2021

Significant capital raised since 2007



Cash position end of December 2019



Imlifidase in kidney transplantation



Kidney transplantation saves lives, reduce costs and increase quality of life incl. societal gains for the society

Several complications and risks with dialysis

- Undergoing dialysis treatment is associated with many complications and side effects incl. cardiovascular diseases¹. In the long term, patients may also eventually lose access to dialysis as a result of failed ports, bad veins, and other factors²
- In general, patients on the kidney transplant waiting list and who are on dialysis have a lower quality of life than non-dialysed patients or patients who have been transplanted³
- First study in Europe on labor market outcomes demonstrates societal gains of enabling transplantation with three times as many transplant patients employed vs. dialysis patients.
- Lastly, extended dialysis is also a high-risk factor for removal from the transplant wait list⁶

¹ Cozzolino et al., 2018

² Sinnakirouchenan and Holley, 2011 Shenoy, 2017

³ Wyld et al., 2012

⁴ Jarl et al. Transplantation, 2018, 102:1375-1381

⁵ NHS blood and transplant, 2018.


⁶ Orandi et al. N Engl J Med 2016;374:940-50

⁷ www.usrds.org

⁸ Shehata et al, Transfus Med Rev 201, 24 Suppl 1: S7-S27

⁹ Jarl et al. Transplantation, 2018, 102:1375-1381

Transplantation leads to better outcomes



*Cost of kidney transplantation and 5 years of immuno-suppression treatment^{6,7}

Imlifidase may enable transplantation in highly sensitized kidney patients

Creating equity for highly sensitized patients

- Allocation systems increase transplantation rates, however the rates for highly sensitized patients are still very low compared with average or non-sensitized patients
- If approved, imlifidase may potentially:
 - Complement allocation systems (e.g. KAS, Euro-transplant) to reduce time to transplant in highly sensitized patients
 - Reduce the need for antibody matching and give sensitized patients access to a larger pool of organs
 - Reduce the risk for co-morbidities and mortality associated with dialysis and waiting time
 - Increase transplant rates in highly sensitized patients
 - Help reduce the number of discarded kidneys (1,000 donated kidneys are discarded in the U.S. alone every year³)

¹ Jordan et al. British Medical Bulletin, 2015, 114:113–125

² Orandi et al. N Engl J Med 2016;374:940-50

³ Organ Procurement and Transplantation Network (OPTN)

⁴ Jordan et al. British Medical Bulletin, 2015, 114:113-125





Delilah, a 23 years old highly sensitized kidney transplant patient from California

U.S. + EU Kidney Transplant Waitlist Breakdown

>30% of waitlist patients are sensitized

- 15% moderately sensitized^{1,2}
- 15% highly sensitized^{1,2 *}



*Patients with sensitivity above cPRA 80%

Source: The U.S. Department of Health and Human Services and .irodat.org

New US Kidney Care reform set out to double kidney organ availability and increase transplantation rates by 2030

Chronic kidney disease is major issue in the US


- In the U.S., approximately 37 million people have chronic kidney disease and more than 700,000 have ESRD¹
- There are nearly 100,000 Americans waiting to receive a kidney transplant and roughly 20,000 patients are being transplanted annually
- The U.S. government is estimated to spend more than \$100 billion annually (~ 20% of traditional Medicare) to treat chronic kidney disease and end-stage renal disease²
- The Health and Human Services (HHS) set out three specific goals for ESRD following the executive order³
 - 1) Reducing the number of Americans developing ESRD by 25 percent by 2030
 - 2) Having 80 percent of new ESRD patients in 2025 either receiving a transplant or homecare dialysis
 - 3) Doubling the number of kidneys available for transplant by 2030

¹ www.cdc.gov

² <https://www.politico.com/story/2019/07/08/trump-kidney-care-market-1573651>

³ www.hhc.gov

Patients in need of kidney transplantation (US)



Source: USRDS Annual Data Report 2016, US HHS Organ Procurement and Transplantation Network
Note: 5-year CAGRs (until 2016 for waiting list and transplantations; 2014 for rest). 1) End stage renal disease

Approximately 10-15% of patients on wait list are highly sensitized

Highly sensitized patients are difficult to match

- Causes of sensitization include



Pregnancy




Blood transfusion



Previous transplantations

- Calculated Panel Reactive Antibodies (cPRA) is a measure for HLA-sensitization
- Inability to match or effectively desensitize patients remains a barrier for transplantation in highly sensitized patients
- Allocation Systems such as KAS and Eurotransplant rely on cPRA score to characterize patients for transplant

US Kidney Waitlist Patients by cPRA in 2018



Source: Organ Procurement and Transplant Network,
Advanced Report. Analysis as of September 25, 2018

High unmet medical need in spite of updated Kidney Allocation System


Imlifidase may potentially complement KAS

- The Kidney Allocation System (KAS) in U.S. was updated in 2014 to prioritize national allocation for highly sensitized patients
- Implementation initially resulted in a bolus effect; however a group of highly sensitized patients are still not helped due to lack of matched organs
- If approved, imlifidase may potentially complement allocation systems like KAS and Euro-transplant and reduce time to transplant in highly sensitized patients

"We thought the KAS would be very good, but the experience was different. I don't think you can have a bureaucratic solution for an immunologic problem, we have to face that we do need drugs to deal not only with acute antibodies but also with the rebound."

Stanley Jordan M.D., Director Kidney Transplantation and Transplant Immunology at the Cedars-Sinai Medical Center in LA.

Significant number of highly sensitized patients remains on the waiting list post KAS



Source:
OPTN/UNOS
Darren Stewart, MS,
UNOS Research Department



Completed and
ongoing studies in
kidney transplantation



Imlifidase has enabled kidney transplantation in 46 highly sensitized patients

Pooled analysis from four Phase 2 trials

- Analysis included 46 patients
 - 50% had a cPRA of 100% (Average 99%)
 - 85% were crossmatch positive
 - 70% were retransplanted
- Donor Specific Antibody (DSA) levels rapidly decreased and all crossmatches were converted to negative, thus enabling transplantation in all patients
- At study completion, all patients alive and graft survival at 94% six months post transplantation.

Study design of our four phase 2 trials

Study 02 Phase 2

Subjects	8 patients 
Design	Single-center, single-arm, open-label
Main objective	Efficacy defined as Imlifidase dosing scheme resulting in HLA antibody levels acceptable for transplantation, within 24 hours

Study 03 Phase 2

Subjects	10 patients 
Design	Single-center, single-arm, open-label, no prior desensitization
Main objective	Safety in the transplantation setting and efficacy defined as HLA antibody levels acceptable for transplantation

Study 04 Phase 2

Subjects	17 patients  
Design	Investigator initiated, Single-center, single-arm, open-label. All patients had prior desensitization with IVIG and/or PLEX
Main objective	Safety in combination with Cedars Sinai's "standard protocol" for desensitization of highly sensitized patient

Study 06 Phase 2

Subjects	18 patients   
Design	Multicenter, multinational, single-arm, open-label
Main objective	Efficacy in creating a negative crossmatch test

Study 01 Phase 1

The 01 study showed complete removal of IgG and that Imlifidase was considered safe to use

Efficacy

- ✓ Rapid degradation of IgG in serum in subjects dosed with 0.12 and 0.24 mg/kg imlifidase. Imlifidase had full effect within 6 hours. The entire IgG pool was converted into F(ab')₂ and Fc-fragments. Maximal effect was accomplished 2-6 hours after dosing.

Safety

- ✓ Newly synthesized intact IgG was clearly detectable in all subjects after 1-2 weeks after dosing. After 3 weeks the level of intact IgG constituted the main IgG fraction in serum

CLINICALTRIALS.GOV ID

NCT01802697 (2013/2014)

SUBJECTS

29 (20 active plus 9 placebo) healthy subjects (Sweden)

DOSES/FOLLOW UP TIME

The starting dose was 0.01 mg/kg BW and the highest dose group received 0.24 mg/kg BW

MAIN OBJECTIVES

- The objectives were to assess safety, efficacy in IgG cleavage, pharmacokinetics and immunogenicity of imlifidase following intravenous administration


STUDY DESIGN

- Randomized placebo-controlled dose-escalation study with 29 (20 active plus 9 placebo) healthy subjects

STATUS

Completed

- The 01 study showed complete removal of IgG and that Imlifidase was considered safe to use




Study 02 Phase 2

The 02 study showed that 1-2 doses of imlifidase at 0.25 mg/kg BW resulted in HLA antibody levels acceptable for transplantation¹

- ✓ Imlifidase is well tolerated in patients with chronic kidney disease
- ✓ Efficacy results strongly support further development in the patient population
- ✓ The first HLA-incompatible transplantation ever after desensitization with imlifidase was performed in one of these patients (2014)

HLA-antibody levels before and after 6 hours treatment with imlifidase




¹ Lorant et al (2018) American Journal of Transplantation (2018)

Study 03 Phase 2


The 03 study proofed safety and efficacy with HLA antibodies at acceptable levels; enabling transplantation in all patients

Analysis of IgG in patient serum before and after imlifidase treatment



SDS-PAGE analysis of patient serum

Analysis of complement binding HLA antibodies before and after imlifidase



CLiQ analysis of patient serum

Protocol





Study 04 Phase 2

The 04 study proofed safety and efficacy with Cedar Sinai's standard protocol (rituximab and IVIg)

Cedar's desensitization protocol in combination with imlifidase

Graft function (eGFR) post six months



CLINICALTRIALS.GOV ID

NCT024226684

SUBJECTS

17 Patients (US)

DOSES/FOLLOW UP TIME

0.24 mg/kg 180 days

MAIN OBJECTIVES

- Safety in combination with Cedars Sinai's "standard protocol" for desensitization of highly sensitized patients
- Efficacy in preventing AMR

COMMENTS

- Investigator initiated study
- Investigator sponsored IND
- Imlifidase to desensitize patients previously treated with rituximab and IVIg
- Deceased donors only


STATUS

Completed


Study 06 Phase 2

The 06 study showed proofed safety and efficacy thereby making highly sensitized patients eligible for kidney transplantation


Graft function (eGFR) post imlifidase



DSA level pre-dose and post imlifidase



Protocol



Jordan SC, et al. (2019).

Results from the international phase II study on the safety and efficacy of imlifidase in highly-sensitized kidney transplant patients. Abstract presented at ATC.

Overview of all completed studies with imlifidase in transplantation

STUDY	SUBJECTS/ COUNTRY	STUDY DESIGN	PRIMARY ENDPOINT	SECONDARY ENDPOINTS	STATUS/ PUBLICATION
Study 01 Phase 1	29 subjects 	Randomized placebo-controlled dose-escalation study with 29 (20 active plus 9 placebo) healthy subjects	Safety and tolerability	Efficacy in IgG cleavage, the pharmacokinetics (PK) and immunogenicity of imlifidase	Complete PLOS ONE (2015) ¹
Study 02 Phase 2	8 subjects 	Single-center, single-arm, open-label	Dosing resulting in HLA-antibody reduction (MFI<1100)	Efficacy: HLA antibody reduction acceptable for transplantation (MFI <1100 as measured in SAB assay)	Complete Lorant et al (2018) American Journal of Transplantation ²
Study 03 Phase 2	10 subjects 	- Single-center, single-arm, open-label - No prior desensitization	Safety: AEs, clinical laboratory tests, vital signs, ECGs	Efficacy: HLA antibody reduction acceptable for transplantation (MFI <1100 as measured in SAB assay)	Complete The New England Journal of Medicine (2017) ³
Study 04 Phase 2	17 subjects 	- Investigator initiated study, Single-center, single-arm, open-label - All patients had prior desensitization with IVIG and/or plasmapheresis	- Assessment of efficacy in eliminating DSAs in DSA and flow cytometry positive, highly sensitized patients - Assessment of safety - Assessment of efficacy/kidney function	- Serum creatinine (0-6 months) - Proteinuria (0-6 months) - DSA at multiple timepoints posttransplant (day 0, D30, D90, D180)	Complete The New England Journal of Medicine (2017) ³
Study 06 "Highdes" Phase 2	18 subjects 	Multicenter, multinational, single-arm, open-label Included pts who may have had prior unsuccessful desensitization or pts in whom it was unlikely to be effective	Crossmatch conversion in DSA+ patients who have a positive XM test to their available LD or DD	- DSA reduction at multiple timepoints (2, 6, 24, 48 h after imlifidase) - Time to create negative CDC XM test and/or flow cytometry (FACS) XM test - Safety	Complete Annals of Surgery (Lonze et al, only New York patients) Montgomery et al ATC abstract (2019) ⁴
Long-term follow-up study	Up to 46 subjects 	A prospective, observational long-term follow-up study of patients treated with imlifidase prior to kidney transplantation	Long-term graft survival in patients who have undergone kidney transplantation after imlifidase administration	- Patient survival, kidney function, comorbidity, treatments and QoL - Safety - DSA - Immunogenicity	Ongoing

¹ Winstedt et al., "Complete Removal of Extracellular IgG Antibodies in a Randomized Dose Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity", PLOS ONE 2015, 10(7)

² Lorant et al., "Safety, immunogenicity, pharmacokinetics and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients" Am J Transplant. 2018 Nov;18(11):2752-2762

³ Jordan et al., "IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation", N Engl J Med 2017;377:442-53.

⁴ Montgomery et al., "Safety And Efficacy Of Imlifidase In Highly-sensitized Kidney Transplant Patients: Results From A Phase 2 Study" ATC Abstract, 2019

Medical Advisory Board



Professor Stanley Jordan

(Chairman) M.D., Ph.D., Director of Kidney Transplantation and Transplant Immunology, Kidney and Pancreas Transplant Center and Director of Division of Pediatric and Adult Nephrology, Cedars-Sinai Medical Center, Los Angeles, California



Professor Robert Montgomery

M.D., Ph.D., FACS, Director at NYU Langone Transplant Institute, New York, NY, USA



Professor Christophe Legendre

M.D., Ph.D. Professor at Paris Descartes University and Head of the Adult Nephrology and Transplantation unit at Necker Hospital in Paris.



Professor Kathryn Wood

Ph.D. Fellow of the Academy of Medical Sciences, Professor of Immunology in the Nuffield Department of Surgical Sciences, University of Oxford, England, runs the Transplantation Research Immunology Group




CMC - Imlifidase



Imlifidase, a novel approach to effectively eliminate pathogenic IgG


Proven mechanism of action

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')₂ fragment and one homo-dimeric Fc-fragment



Inactivation of IgG in human serum

- Rapid onset of action that takes down IgG below detectable level in 2 hours post 15 min infusion
- IgG antibody-free window for approximately one week




Our IgG antibody-cleaving enzyme

Origins from *Streptococcus pyogenes*

- Cysteine protease derived from an Immunoglobulin G (IgG)-degrading enzyme of *Streptococcus pyogenes*
- Contains only one cysteine - no disulfide bridges
- Monomeric protein with a molecular mass of 35 Kilo Dalton
- Isoelectric point of 6.1
- The coding gene for imlifidase is cloned and expressed in *Escherichia coli*

Imlifidase consists of 311 amino acids



Imlifidase is a lyophilized product formulation with a shelf life of 12 months at 2-8° Celsius storage

Imlifidase will be infused in 15 minutes

- The product for commercial supply will be a lyophilized (cold chain) powder concentrate (11 mg solution) for infusion currently with a claimed shelf life of 12 months at 2-8°C storage. Ongoing stability studies indicate a shelf life of at least 24 months.
- Each vial is filled with 1.2 mL of a 10 mg/mL solution before freeze drying (=12 mg). Extractable volume after reconstitution with 1.2 mL sterile water is 1.1 mL of 10 mg/mL solution - resulting in 11 mg product
- The protein concentration, 10 mg/mL, has desirable characteristics with respect to not form aggregates
- Continuous stability programs ongoing to study changes in protein characteristics and performance.
- Imlifidase dose is clinically set to 0.25 mg/kg bodyweight (11 mg / 0.25 mg/kg = 44 kg (BW) / vial content) 2R vial size is suitable for the content



Drug product composition

- Imlifidase protein
- Mannitol
- Tween
- EDTA
- Tris-HCl

Supply Chain for imlifidase in kidney transplantation



Manufacturing will be done in close collaboration with highly experienced European based third party CMOs

Drug substance production process (API)

Biotechpharma



Fermentation/ harvesting

- Working Cell Bank
- Pre-Cultivation
- Main Cultivation
- Cell Harvest

Protein purification

- Cell Disruption
- Protein Release

Protein purification cont.


- Ion Exchange Chromatography
- Ceramic Hydroxy Apatite Chromatography
- Hydrophobic Interaction Chromatography
- Ultrafiltration/ Diafiltration

Filling

- Formulation, filtration, filling and storage (-80°C)

Drug product production process (upscaling)

Baxter



Thawing of drug substance

Compounding of drug product solution

Bioburden (pre-filtration)

In-line sterile filtration and aseptic filling

Storage 2-8°C

Packaging

Capping, outer decontamination

Lyophilization (14 h + 7.5 h)

biotechpharma

Facts

- Based in Vilnius, Lithuania
- Start-up Year: 2004
- Capacity: 300 L fermentor (1000 L fermentor in 2020)
- Certifications: GMP compliance, Manufacturing authorization license
- Inspections: National regulatory agency (EU), EU/US customer inspections, FDA mock inspection

Baxter

Facts

- Based in Halle/Westfalen Germany
- Start-up Year: 2001 (contract manufacturing)
- Capacity: 6-35 L drug product solution per batch (5,000-30,000 vials)
- Certifications: GMP compliance, Manufacturing authorization license
- Inspections: National regulatory agency (EU), FDA, EU/US customer inspections

HANSA
BIOPHARMA

Clinical development programs



Broad pipeline in transplantation and auto-immune diseases

Candidate / Projecting	Indication	Research/ Preclinical	Phase 1 ¹	Potentially Pivotal program/ Phase 2 ²	Marketing Authorization	Marketed	Next Anticipated Milestone
Imlifidase	Kidney transplantation in highly sensitized patients				*)		EU: CHMP Opinion US: Initiation of clinical study to support BLA submission in 2023
	Anti-GBM antibody disease						Complete enrolment
	Antibody mediated kidney transplant rejection (AMR)						Complete enrolment
	Guillain-Barré syndrome						Complete enrolment
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology						Development of CMC process / Tox studies
EnzE	Cancer immunotherapy						Research phase



Completed



Ongoing

¹ Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7).

² Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)

*) EMA: In imlifidase for kidney transplantation we have filed for conditional approval after completion of phase 2.
A post-approval study would need to be executed in case of approval.

FDA: Agreement with the FDA on a regulatory path forward in the US. New clinical study to support BLA submission by 2023

Anti-GBM, a rare acute autoimmune disease affecting kidneys and lungs

2/3 of Anti-GBM patients lose their kidneys²

- Indication: Antibodies are directed against an antigen intrinsic to the glomerular basement membrane (GBM) causing acute injury of kidney and/or lung
- Anti-GBM affects one in a million annually (~900 worldwide^{1,2}) with majority of patients lose kidneys², requiring chronic dialysis and kidney transplantation.
- The study is an open label investigator-initiated Phase 2 with Professor Mårten Segelmark at Linköping University Hospital as the sponsor and principal investigator
- The study is designed to evaluate the safety and tolerability of imlifidase in patients with severe anti-GBM disease on top of standard care consisting of plasmapheresis, steroids and cyclophosphamide.
- 14/15 patients enrolled in anti-GBM. Completion of enrollment expected in Q1 2020. 14 sites recruiting. Topline data read out expected in second half 2020
- Our Anti-GBM program obtained Orphan Drug designation from both FDA and European Commission (2018)

1 Kluth et al. J Am Soc Nephrol. 1999 Nov;10(11):2446-53

2 Hellmark et al. J Autoimmun. 2014 Feb-Mar;48-49:108-12



Anti-GBM Phase 2

Favourable pre-clinical studies show that imlifidase degrades IgG bound to the GBM in vivo; preventing renal damage in animals

CLINICALTRIALS.GOV ID

NCT03157037 (Since March 2017)

SUBJECTS

15 patients targeted. Patients will be monitored for six months
Recruitment at 15 clinics

DOSES/FOLLOW UP TIME

Dosage 0.25mg/kg 180 days follow up

MAIN OBJECTIVES

- Primary objective is to evaluate the safety and tolerability of imlifidase on background of standard of care, and assess efficacy based on renal function at six months after treatment


STUDY DESIGN

- Open label, multicenter, single arm Phase 2 study with adverse renal prognosis
- Investigator initiated study

STATUS

Ongoing

Mouse anti-rabbit IgG (Fc specific)



Inclusion criteria


Inclusion: Toxic anti-GBM antibodies level as considered by the investigator. eGFR < 15 ml/min/1.73 m² or if the patient is non-responsive to standard treatment, and has lost >15 ml/min/1.73 m² after start of treatment

Exclusion: Anuria for more than 2 days (less than 200 ml during last 48 hours); Dialysis dependency for more than 5 days

Yang et al. Favorable pre-clinical studies: "Imlifidase degrades IgG bound to the GBM in vivo, thereby preventing renal damage in this animal model. Nephrology Dialysis Transplantation, 2010;25(8): 2479-86.

Anti-GBM creatinine and antibody concentration

- Both creatinine and levels of antibodies predict outcome and we expect that imlifidase can treat the disease by degrading IgG bound to the GBM



Long term graft survival is challenged by antibody mediated rejection post transplantation

There is no approved treatment for AMR

- Active antibody mediated rejection after transplantation occurs in 10-15% of kidney transplants¹ or ~ 3,200^{2,3} patients annually⁴ and is a significant challenge to long term graft survival
- Today's standard of care include plasma exchange, and treatment with steroid and IVIg. AMR patients not treated successfully risk graft failure, dialysis and return to the waitlist
- The AMR Phase 2 study is a randomized, open-label, multi-center, active control study designed to evaluate the safety and efficacy of imlifidase in eliminating donor specific antibodies (DSAs) in the treatment of active episodes of acute AMR in kidney transplant patients.
- 2/30 patient treated with imlifidase in AMR. 6/8 sites have been initiated to recruit patients in the US, Europe and Australia. Enrollment expected to be completed H2 2020
- Enrollment is planned to take 12 months with an expected topline data read out 2H 2021

¹ Puttarajappa et al., Journal of Transplantation, 2012, Article ID 193724.

² Jordan et al., British Medical Bulletin, 2015, 114:113-125.

³ <http://www.irodat.org>.

⁴ Seven major markets – US, Germany, UK, France, Spain, Italy, and Japan



AMR Phase 2

New AMR Phase 2 study initiated to test imlifidase ability to reduce the amount of DSA in AMR patients post transplantation

CLINICALTRIALS.GOV ID

NCT03897205 (2019)

SUBJECTS

30 patients targeted (20 patients will be treated with imlifidase and 10 with Plasma exchange). Recruitment from 8 sites in the U.S., EU and Australia.

DOSES/FOLLOW UP TIME

1 dose of imlifidase (0.25 mg/kg) or 5-10 sessions of plasma exchange

MAIN OBJECTIVES

- Imlifidase ability to reduce the amount of DSA in comparison with plasma exchange in patients who have an active AMR post transplantation
- Ensure safety for patients

STUDY DESIGN


- Randomized, open-label multicenter, active control study, designed to evaluate the safety and efficacy of imlifidase in eliminating DSA in active AMR

STATUS

On going

Potential of using imlifidase vs. PLEX in AMR

Illustrative



Guillain-Barré syndrome is an acute autoimmune attack on the peripheral nervous system

GBS can affect anyone at any age

- GBS is an acute autoimmune attack on the peripheral nervous system, which rapidly and progressively weakens extremities.
- Only parts of the patients fully recover from GBS, thus a high unmet medical need for new treatments; 40% lose strength and have pain while mortality is 3-7% mortality
- Addressable population of ~ 11,000¹ per year in 7MM²
- Current Standard of Care is treatment with IVIG or PLEX
- The new Phase 2 study is an open-label, single arm, multi-center study evaluating the safety, tolerability and efficacy of imlifidase in GBS patients in combination with standard of care intravenous immunoglobulin (IVIg)
- First patient dosed with imlifidase in Q4'19. 2/30 patients enrolled in 2019. 6/10 sites are recruiting patients in France and UK. Enrollment expected to be completed in H1 2021
- In 2018, the FDA granted Orphan Drug Designation to imlifidase for the treatment of GBS

¹ McGrogan et al. Neuroepidemiology 2009;32(2):150-63.

² 7MM = Seven major markets – US, Germany, UK, France, Spain, Italy, and Japan



GBS Phase 2

New Phase 2 study initiated in GBS to evaluate safety, tolerability and efficacy of imlifidase in GBS patients

CLINICALTRIALS.GOV ID

NCT03943589 (2019)

SUBJECTS

30 patients targeted
Recruitment at ten clinics in Europe
(France, U.K. and the Netherlands)

DOSES/FOLLOW UP TIME

Dosage 0.25mg/kg follow up 180 days and 12 months

MAIN OBJECTIVES

- safety and effectiveness of imlifidase in patients diagnosed with GBS

STUDY DESIGN


- Study is an open-label, single arm, multi-center trial evaluating safety, tolerability and efficacy of imlifidase, in combination with standard of care, IVIg, to treat GBS

STATUS

Ongoing


Today's Standard of Care IVIg or PLEX

Illustrative



Potential with imlifidase

Illustrative



Pre-clinical programs




“NiceR” – new set of enzymes for repeat dosing; potentially enabling treatment of relapsing diseases

IgG-cleaving enzyme with lower immunogenicity

- Potential application for a broad array of indications, including reoccurring AMR, relapsing autoimmune diseases and oncology
- The first selected promising new drug candidate from the NiceR program is an IgG-cleaving enzyme (cysteine peptidase) with characteristics based on a homolog to imlifidase, but with lowered immunogenicity.
- Development of a GMP-manufacturing process has been initiated

NiceR can potentially inactivate flares




EnzE can potentially improve the therapeutic effect in oncology

Proof of concept demonstrated in vivo for mice

- Enzyme based antibody enhancement through pre-treatment
- The abundance of normal IgG in blood interferes with therapeutic monoclonal antibodies
- Pre-treatment with imlifidase / NiceR has potential to significantly potentiate antibody-based cancer therapies
- Suppressive effect of IVIg on effector cell function abrogated by imlifidase
- Imlifidase can significantly improve the therapeutic effect of rituximab

Mice with human IgG (~9mg/mL)




¹ Järnum et al. Mol Cancer Ther 2017;16:1887-1897

Exploring imlifidase in gene therapy as a potential pre-treatment to inactivate neutralizing antibodies

Nabs are immunological barriers in gene therapy

- Gene therapy programs may exclude up to 40% of patients from clinical studies and approved treatments due to presence of neutralizing antibodies¹
- Most gene programs use viral vectors originating from Adeno-Associated Viruses (AAV) for gene insertions *in vivo*; however in many cases the human immune system have developed preformed neutralizing anti-AAV that prevents effective and safe use
- Today experimental protocols are used based on plasma-pheresis, or with immunosuppressants; however these protocols have not demonstrated sufficient efficacy and safety
- 187 *in vivo* programs are ongoing in gene therapy including 73 clinical stage programs, while two *in vivo* gene therapy products have been approved by FDA (Luxturna from Spark Therapeutics and Zolgensma from Novartis)

Idea is to enable gene therapy despite Nabs



Contact our Investor Relations and Corporate Communications team



Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com



Rolf Gulliksen

Head of Corporate Communications

Mobile: +46 (0) 733-328 634

Email: rolf.gulliksen@hansabiopharma.com

Visit our web site
www.hansabiopharma.com



Calendar

Jan 8, 2020	SEB Nordic Seminar, Copenhagen
Jan 12-15, 2020	JP Morgan Global Healthcare conference, San Francisco
Jan 22, 2020	SEB Annual Pharma & Biotech Seminar, Stockholm
Jan 23, 2020	Road Show RBC London
Feb 6, 2020	Interim Report Oct-Dec 2019
Feb 19-20, 2020	Road Show Kempen Paris/Tel Aviv
Mar 2-3, 2020	Cowen Annual Health Care Conference, Boston
Mar 4, 2020	Carnegie Nordic Healthcare Seminar, Stockholm
Apr 2, 2020	Annual Report 2019
Apr 21-22, 2020	Kempen Life Sciences Conference, Amsterdam
Apr 28, 2020	Interim Report Jan-Mar 2020
May 19-20, 2020	RBC Global Healthcare Conference, NYC
May 26, 2020	ABG Life Science Summit, Stockholm
May 27, 2020	Ökonomisk Ugebrev Life Science Conference, Copenhagen

